SYS-CON MEDIA Authors: Mat Mathews, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aegerion Pharmaceuticals, Inc. - AEGR

NEW YORK, Jan. 9, 2014 /PRNewswire/ -- Pomerantz Gross LLP is investigating claims on behalf of investors of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company"). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 237.

The investigation concerns whether Aegerion and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.  On Thursday, January 09, 2014, shares of Aegerion fell on higher than usual volume after the company announced that it has received a subpoena from the United States Department of Justice, represented by the U.S. Attorney's Office in Boston, MA, requesting documents regarding the Company's marketing and sale of JUXTAPID in the US.

On this news, shares of Aegerion fell $9.25 per share to $64.50, or more than 12.54%, on January 9, 2014.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
[email protected]

SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.